PolarityTE, Inc. (Nasdaq: PTE) announced a business update and financial results for Q1 2022, showing a net revenue decline of 84% year-over-year, primarily due to ceasing SkinTE sales and reduced COVID-19 testing. The FDA granted SkinTE RMAT designation, enabling expedited development. Cash and equivalents stood at $18.7 million. Operating loss increased by 8%, attributed to lower revenues, while the net loss significantly decreased by 78% to $3.77 million. The company divested its preclinical research unit, enhancing focus on advancing SkinTE development.
PolarityTE, Inc. (Nasdaq: PTE) announced that the FDA has granted RMAT designation for its SkinTE product. This designation aims to expedite the development and review of regenerative medicine therapies, benefiting companies like PolarityTE in navigating the regulatory landscape. CEO Richard Hague highlighted the importance of this designation in addressing unmet medical needs and expressed optimism about collaborations with the FDA. PolarityTE is now pursuing pivotal studies for SkinTE, essential for biologics license application.
PolarityTE, Inc. (Nasdaq: PTE) is set to release its financial results for the quarter ending March 31, 2022, on May 16, 2022, at approximately 7:30 a.m. Eastern Time. A conference call with Q&A will follow at 8:30 a.m. Eastern Time. Investors can access the call by dialing 1-800-289-0459 and using passcode 399675. The company is developing SkinTE®, a regenerative tissue product, and is pursuing pivotal studies required for a biologics license application with the FDA.
PolarityTE, Inc. (Nasdaq: PTE) has enrolled the first subject in its Phase III study, titled 'COVER DFUs', focusing on the treatment of Wagner grade 2 diabetic foot ulcers (DFUs) using SkinTE. This pivotal study will involve 100 subjects across 20 U.S. clinical sites, comparing SkinTE in conjunction with standard care against standard care alone. The primary endpoint evaluates DFU closure at 24 weeks, with secondary endpoints addressing quality of life and infection rates. This marks a significant milestone in the company's exploration of chronic cutaneous ulcers, a growing market.
PolarityTE, Inc. (PTE) reported its financial results for the year ended December 31, 2021, showing a 30% decrease in net loss to $29.3 million compared to the previous year. Noteworthy is the FDA approval of its IND application for SkinTE aimed at treating chronic cutaneous ulcers, with the first patient treatment anticipated in April 2022. The company's net revenues fell by 7%, driven by the cessation of SkinTE commercial sales in May 2021. Operating expenses decreased by 25%, highlighting ongoing cost-cutting efforts. As of December 31, 2021, cash and equivalents stood at $19.4 million, raising concerns about financing beyond 2022.
PolarityTE, Inc. (Nasdaq: PTE) has successfully closed a registered direct offering with a single institutional investor, raising approximately $5.0 million. The offering consists of 3,000,000.435 shares of Series A and 2,000,000.29 shares of Series B convertible preferred stock, convertible into 16,393,445 shares of common stock. Additionally, investors received warrants to purchase up to 16,393,445 shares of common stock at an exercise price of $0.35 per share. The funds will be used for working capital and general corporate purposes.
PolarityTE, Inc. (Nasdaq: PTE) has announced a securities purchase agreement with a single institutional investor for a registered direct offering, raising approximately $5.0 million. The deal includes 3,000 shares of Series A convertible preferred stock, 2,000 shares of Series B convertible preferred stock, and warrants for up to 16,393,445 shares of common stock. Preferred stock has a stated value of $1,000 per share and a conversion price of $0.305. Proceeds will be used for working capital and general corporate purposes. The offering is expected to close around March 16, 2022.
PolarityTE, Inc. (Nasdaq: PTE) will announce its financial results for the year ending December 31, 2021, on March 30, 2022, at 7:30 a.m. Eastern Time. A conference call will follow at 8:30 a.m. ET, featuring a Q&A session. Investors can access the call by dialing the provided numbers or via a webcast. The company is known for developing regenerative tissue products, specifically SkinTE®, which is currently under investigation with the FDA for chronic cutaneous ulcer treatment. Further details are available on the company's website.
PolarityTE, Inc. (PTE) announced the allowance of its fourth patent in the U.S. from the USPTO for its minimally polarized functional unit (MPFU) technology, filed on May 21, 2021. This development enhances the company's intellectual property portfolio, crucial for protecting its regenerative tissue technology, notably SkinTE®. CEO Richard Hague emphasized the importance of this patent in supporting regulatory approvals and advancing clinical studies. PolarityTE is set to initiate the first of two Phase 3 studies for SkinTE® to support a biologics license application.
PolarityTE (Nasdaq: PTE) has received FDA approval for its investigational new drug (IND) application aimed at evaluating SkinTE in treating chronic cutaneous ulcers. This approval allows the company to initiate its first pivotal study, named COVER DFUs, with plans to enroll 100 patients across 20 U.S. sites. The study will assess the effectiveness of SkinTE combined with standard care against standard care alone, focusing on wound closure rates at 24 weeks. This milestone represents a significant step forward for PolarityTE and its strategic focus on addressing complex wound care challenges.